IPP Bureau
Market success of Novo Nordisk’s obesity drug likely to be delayed in Japan, says GlobalData
By IPP Bureau - July 29, 2023
In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1
Upsurge in pink eye conjunctivitis cases in the country
By IPP Bureau - July 29, 2023
Take proper precautions and seek timely treatment!
Dr. Reddy's Laboratories Q1 FY2024 consolidated PAT jumps to Rs. 1402.5 Cr
By IPP Bureau - July 28, 2023
The company has reported total income of Rs. 6738.4 crores during the period ended June 30, 2023
Astec LifeSciences posts consolidated Q1FY24 loss at Rs. 8.19 Cr
By IPP Bureau - July 28, 2023
Astec LifeSciences has reported total income of Rs. 144.55 crores during the period ended June 30, 2023
Laurus Labs posts decline in Q1FY24 consolidated PAT to Rs. 24.85 Cr
By IPP Bureau - July 28, 2023
The company has reported total income of Rs. 1185.39 crores during the period ended June 30, 2023
Dr. Lal Path Labs Q1FY24 consolidated PAT up at Rs. 82.6 Cr
By IPP Bureau - July 28, 2023
Dr. Lal Path Labs Ltd. has reported total income of Rs. 555.4 crores during the period ended June 30, 2023
Ajanta Pharma's Q1 FY24 consolidated PAT up at Rs. 208.12 Cr
By IPP Bureau - July 28, 2023
The company has reported total income of Rs. 1052.79 crores during the period ended June 30, 2023
Biocon Foundation releases 2nd edition of consensus guidelines for head & neck cancer
By IPP Bureau - July 28, 2023
Marks the World Head & Neck Cancer Day at the OCTF Conference
GenWorks introduces mechanical hysteroscopic tissue removal system
By IPP Bureau - July 28, 2023
Uses a simple mechanical approach for removing intrauterine tissues
Cipla reports jump in Q1FY24 consolidated PAT to Rs. 995.70 Cr
By IPP Bureau - July 27, 2023
Cipla has reported total income of Rs. 6465.18 crores during the period ended June 30, 2023
Eugia Pharma receives USFDA approval for Plerixafor Injection
By IPP Bureau - July 26, 2023
The approved product has an estimated market size of around US$ 210 million for the twelve months ending May 2023
TransCure bioServices partners with Preclina to expands reach into APAC
By IPP Bureau - July 26, 2023
Preclina is renowned for its highly specialized services in autoimmune and inflammatory disorders
Teva Pharmaceuticals engages Honeywell to help reduce carbon impact
By IPP Bureau - July 26, 2023
Teva will leverage Honeywell’s ‘Energy as a Service’ (EaaS) model
InnoCare gets approval of clinical trial of Zurletrectinib for the treatment of pediatric patients in China
By IPP Bureau - July 26, 2023
Zurletrectinib was developed to treat advanced or metastatic solid tumors harboring NTRK fusion genes
